{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:12Z","timestamp":1740107712956,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10067-018-4290-0","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T19:27:03Z","timestamp":1537817223000},"page":"3275-3284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The effect of extra-articular manifestations on tumor necrosis factor-\u03b1 inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry"],"prefix":"10.1007","volume":"37","author":[{"given":"Yunsuek","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-7140","authenticated-orcid":false,"given":"Hyun-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"issue":"18","key":"4290_CR1","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349\u20131356. \n                    https:\/\/doi.org\/10.1056\/NEJMoa012664","journal-title":"N Engl J Med"},{"issue":"9","key":"4290_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"J Braun","year":"2003","unstructured":"Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62(9):817\u2013824","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4290_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582\u2013591. \n                    https:\/\/doi.org\/10.1002\/art.20852","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4290_CR4","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230\u20133236. \n                    https:\/\/doi.org\/10.1002\/art.11325","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4290_CR5","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136\u20132146. \n                    https:\/\/doi.org\/10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4290_CR6","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402\u20133412. \n                    https:\/\/doi.org\/10.1002\/art.23969","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4290_CR7","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 69(11):2002\u20132008. \n                    https:\/\/doi.org\/10.1136\/ard.2009.124446","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4290_CR8","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/rheumatology\/kev001","volume":"54","author":"JL Rosales-Alexander","year":"2015","unstructured":"Rosales-Alexander JL, Balsalobre Aznar J, Perez-Vicente S, Magro-Checa C (2015) Drug survival of anti-tumour necrosis factor alpha therapy in spondyloarthropathies: results from the Spanish emAR II study. Rheumatology (Oxford, England) 54(8):1459\u20131463. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kev001","journal-title":"Rheumatology (Oxford, England)"},{"issue":"3","key":"4290_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00296-015-3380-4","volume":"36","author":"LM Bearne","year":"2016","unstructured":"Bearne LM, Byrne AM, Segrave H, White CM (2016) Multidisciplinary team care for people with rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int 36(3):311\u2013324. \n                    https:\/\/doi.org\/10.1007\/s00296-015-3380-4","journal-title":"Rheumatol Int"},{"issue":"1","key":"4290_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rodevand E, Koldingsnes W, Kaufmann C, Kvien TK (2011) Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 70(1):157\u2013163. \n                    https:\/\/doi.org\/10.1136\/ard.2010.131797","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4290_CR11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72(7):1149\u20131155. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2012-201933","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4290_CR12","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","volume":"45","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Watson KD, Silman AJ, Symmons DP (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford, England) 45(12):1558\u20131565. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kel149","journal-title":"Rheumatology (Oxford, England)"},{"issue":"9","key":"4290_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","volume":"48","author":"D Elewaut","year":"2009","unstructured":"Elewaut D, Matucci-Cerinic M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford, England) 48(9):1029\u20131035. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kep146","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"4290_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 74(1):65\u201373. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-203582","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4290_CR15","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/ard.2006.052092","volume":"65","author":"S Guignard","year":"2006","unstructured":"Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, Dougados M (2006) Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 65(12):1631\u20131634. \n                    https:\/\/doi.org\/10.1136\/ard.2006.052092","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4290_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","volume":"41","author":"D Wendling","year":"2011","unstructured":"Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis E, Direz G, Ferrazzi V, Ristori JM (2011) New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 41(3):503\u2013510. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2011.05.005","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"4290_CR17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/ard.2002.004861","volume":"62","author":"AM Chorus","year":"2003","unstructured":"Chorus AM, Miedema HS, Boonen A, Van Der Linden S (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62(12):1178\u20131184","journal-title":"Ann Rheum Dis"},{"key":"4290_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12891-015-0489-2","volume":"16","author":"D Wu","year":"2015","unstructured":"Wu D, Guo YY, Xu NN, Zhao S, Hou LX, Jiao T, Zhang N (2015) Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord 16:19. \n                    https:\/\/doi.org\/10.1186\/s12891-015-0489-2","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"4290_CR19","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acr.20258","volume":"62","author":"LE Kristensen","year":"2010","unstructured":"Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P (2010) Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res 62(10):1362\u20131369. \n                    https:\/\/doi.org\/10.1002\/acr.20258","journal-title":"Arthritis Care Res"},{"issue":"9","key":"4290_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3346\/jkms.2014.29.9.1205","volume":"29","author":"JH Kang","year":"2014","unstructured":"Kang JH, Park DJ, Lee JW, Lee KE, Wen L, Kim TJ, Park YW, Lee SS (2014) Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci 29(9):1205\u20131211. \n                    https:\/\/doi.org\/10.3346\/jkms.2014.29.9.1205","journal-title":"J Korean Med Sci"},{"issue":"3","key":"4290_CR21","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th AJTL, Kallenberg CG, Spoorenberg A (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 13(3):R94. \n                    https:\/\/doi.org\/10.1186\/ar3369","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"4290_CR22","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1007\/s10198-014-0598-0","volume":"15","author":"K Gulyas","year":"2014","unstructured":"Gulyas K, Bodnar N, Nagy Z, Szamosi S, Horvath A, Vancsa A, Vegh E, Szabo Z, Szucs G, Szekanecz Z, Szanto S (2014) Real-life experience with switching TNF-alpha inhibitors in ankylosing spondylitis. The European journal of health economics : HEPAC : health economics in prevention and care 15(Suppl 1):S93\u2013S100. \n                    https:\/\/doi.org\/10.1007\/s10198-014-0598-0","journal-title":"The European journal of health economics : HEPAC : health economics in prevention and care"},{"key":"4290_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13075-016-0969-2","volume":"18","author":"A Ciurea","year":"2016","unstructured":"Ciurea A, Exer P, Weber U, Tamborrini G, Steininger B, Kissling RO, Bernhard J, Scherer A (2016) Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther 18:71. \n                    https:\/\/doi.org\/10.1186\/s13075-016-0969-2","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"4290_CR24","doi-asserted-by":"publisher","first-page":"e0168005","DOI":"10.1371\/journal.pone.0168005","volume":"11","author":"A Fisher","year":"2016","unstructured":"Fisher A, Bassett K, Goel G, Stanely D, Brookhart MA, Freeman HR, Wright JM, Dormuth CR (2016) Heterogeneity in comparisons of discontinuation of tumor necrosis factor antagonists in rheumatoid arthritis\u2014a meta-analysis. PLoS One 11(12):e0168005. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0168005","journal-title":"PLoS One"},{"issue":"3","key":"4290_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/rheumatology\/kev374","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, Gomez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford, England) 55(3):523\u2013534. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kev374","journal-title":"Rheumatology (Oxford, England)"},{"issue":"9","key":"4290_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20090","volume":"20","author":"M Corbett","year":"2016","unstructured":"Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, Moe-Byrne T, Fox D, Marzo-Ortega H, Kay L, Woolacott N, Palmer S (2016) Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health technology assessment (Winchester, England) 20(9):1\u2013334, v-vi. \n                    https:\/\/doi.org\/10.3310\/hta20090","journal-title":"Health technology assessment (Winchester, England)"},{"issue":"8","key":"4290_CR27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10654-013-9873-0","volume":"29","author":"LC Thygesen","year":"2014","unstructured":"Thygesen LC, Ersboll AK (2014) When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol 29(8):551\u2013558. \n                    https:\/\/doi.org\/10.1007\/s10654-013-9873-0","journal-title":"Eur J Epidemiol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4290-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T03:42:52Z","timestamp":1569382972000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4290-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4290"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4290-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"assertion":[{"value":"25 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research complied with the Helsinki Declaration. Informed consent was obtained from all enrolled participants. The same informed consent form (ICF) and study protocol were provided to the independent institutional review boards\/ethics committees (IRB\/EC) at each medical center, and each IRB\/EC reviewed the appropriateness of the protocol, risks, and benefits to the study participants. Ultimately, the IRB\/EC independently approved this study without revision of the ICF or study protocol.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}